Helper-free rescue of recombinant negative strand RNA virus
View Patent ↗The present invention relates methods of generating infectious negative-strand virus in host cells by an entirely vector-based system without the aid of a helper virus. In particular, the present invention relates methods of generating infectious recombinant negative-strand RNA viruses intracellularly in the absence of helper virus from expression vectors comprising cDNAs encoding the viral proteins necessary to form ribonucleoprotein complexes (RNPs) and expression vectors comprising cDNA for genomic viral RNA(s) (vRNAs) or the corresponding cRNA(s). The present invention also relates to methods of generating infectious recombinant negative-strand RNA viruses which have mutations in viral genes and/or which express, package and/or present peptides or polypeptides encoded by heterologous nucleic acid sequences. The present invention further relates the use of the recombinant negative-strand RNA viruses or chimeric negative-strand RNA viruses of the invention in vaccine formulations and pharmaceutical compositions.
1. A method for producing influenza virus particles for preparation of a vaccine, comprising:
growing reassortant influenza viruses to produce virus particles and recovering said produced virus particles, wherein said reassortant influenza viruses are produced in cultured cells in the absence of helper virus by introducing into said cultured cells expression vectors sufficient to produce in said cells the genomic vRNA or antigenomic vRNA (cRNA) segments of said reassortant influenza viruses and producing in said cells a nucleoprotein and an RNA dependent RNA polymerase so that RNP complexes containing the genomic vRNA segments of said reassortant influenza viruses are formed
wherein said expression vectors encode HA, NA, non-HA and non-NA vRNA segments and wherein the HA and NA vRNA segments are HA and NA vRNA segments of a viral strain different from a strain that contains all of the non-HA and non-NA vRNA segments.
2. The method of claim 1 , wherein one or more further expression vectors are employed in said cells to express one or more proteins selected from said nucleoprotein and subunits of a RNA-dependent RNA polymerase.
3. The method of claim 1 , wherein a cell line was employed which was capable of expressing one or more of said nucleoprotein and the subunits of a RNA-dependent RNA polymerase.
4. The method of claim 1 , wherein said virus is an influenza virus of type A, B or C.
5. The method of claim 1 , wherein said cells were selected from Vero cells and other cells which are deficient in interferon activity and capable of supporting growth of said viruses.
6. The method of claim 1 , wherein said expression vectors were capable of expressing genomic vRNA segments of said viruses.
7. The method of claim 1 , wherein said growing of reassortant influenza viruses to produce virus particles occurs in an egg.
8. The method of claim 1 , wherein all the required expression vectors were cotransfected into said cells by use of a liposomal transfection reagent, by calcium phosphate precipitation, or by electroporation.
9. The method of claim 1 , wherein each of said expression vectors was a plasmid.
10. The method of claim 2 , wherein each of said expression vectors was a plasmid.
11. The method of claim 1 , wherein each vRNA segment of said viruses or the corresponding cRNAs was present in a separate expression vector.
12. The method of claim 1 , wherein the expression of each vRNA segment or cRNA was under the control of a promoter sequence derived from a mammalian Pol I promoter.
13. The method of claim 12 , wherein said promoter sequence was a truncated human Pol I promoter sequence consisting of nucleotides −250 to −1 of the corresponding native promoter or a functional derivative thereof.
14. The method of claim 1 , wherein the coding sequence for each vRNA segment or cRNA in said expression vectors was followed by a ribozyme sequence or transcription terminator to ensure a correct 3′ end of each said RNA.
15. The method of claim 2 , wherein expression of one or more viral proteins from said further expression vectors was under the control of a regulatory sequence selected from the adenovirus 2 major late promoter linked to the spliced tripartite leader sequence of human adenovirus type 2 or the human cytomegalovirus immediate-early promoter, or a functional derivative of said regulatory sequence.
16. A method for producing influenza virus particles comprising producing in a cell all of the genomic RNA of an influenza virus by expressing from DNA introduced into the cell at least one or more of genomic RNA or cRNA of the influenza virus and producing in the cell RNA dependent RNA polymerase and nucleoprotein and assembling in the cell the influenza virus, said cell being free of helper virus, wherein said cell is selected from Vero cells and other cells which are deficient in interferon activity and capable of supporting growth of said virus.
17. The method of claim 16 , wherein said virus is an influenza virus of type A, B or C.
18. The method of claim 1 , wherein said reassortant influenza viruses are at least 99% free from contaminating viruses.
19. A method for producing influenza virus particles for preparation of a vaccine, comprising:
growing a reassortant influenza virus to produce virus particles and recovering said produced virus particles, wherein said reassortant influenza virus is produced in cultured cells in the absence of helper virus by introducing into said cultured cells expression vectors to produce in said cells the genomic vRNA or antigenomic vRNA (cRNA) segments of a reassortant influenza virus and producing in said cells a nucleoprotein and an RNA dependent RNA polymerase so that RNP complexes containing the genomic vRNA segments of said reassortant influenza virus are formed,
wherein said expression vectors encode at least 4 different vRNA (or cRNA) segments and wherein each said different vRNA segment is from a single influenza virus strain, wherein all said different vRNA segments are not from the same influenza virus strain, wherein said different vRNA segments include an HA and an NA vRNA segment both of which are from the same influenza virus strain, and wherein said different vRNA segments are selected from PB2, PRI, PA, HA, NP, NA, M and NS.
20. The method of claim 19 , wherein said expression vectors encode at least 5 different vRNA segments.
21. The method of claim 19 , wherein said expression vectors encode at least 6 different vRNA segments.
22. The method of claim 19 , wherein said expression vectors encode at least 7 different vRNA segments.
23. The method of claim 19 , wherein said expression vectors encode 8 different vRNA segments.
24. The method of claim 19 , wherein all of said different vRNA segments other than HA and NA are from the same influenza virus strain.